The estimated Net Worth of Gordon Ringold is at least $293 Thousand dollars as of 30 May 2018. Gordon Ringold owns over 10,000 units of Ardelyx Inc stock worth over $149,000 and over the last 10 years he sold ARDX stock worth over $0. In addition, he makes $144,485 as Independent Director at Ardelyx Inc.
Gordon has made over 4 trades of the Ardelyx Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of ARDX stock worth $40,000 on 30 May 2018.
The largest trade he's ever made was buying 15,000 units of Ardelyx Inc stock on 21 March 2016 worth over $116,550. On average, Gordon trades about 4,545 units every 99 days since 2014. As of 30 May 2018 he still owns at least 25,000 units of Ardelyx Inc stock.
You can see the complete history of Gordon Ringold stock trades at the bottom of the page.
Dr. Gordon Ringold, Ph.D. is Independent Director of the Company. Dr. Ringold has served as the President and CEO of Quadriga BioSciences, Inc., a biotechnology company, since January 2015. From March 2000 to December 2013, Dr. Ringold served as Chairman and Chief Executive Officer of Alavita, Inc., a biotechnology company. From June 2001 until September 2016, Dr. Ringold served as a director of Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA). Dr. Ringold received a Ph.D. in microbiology from the University of California, San Francisco, in the laboratory of Dr. Harold Varmus before joining the Stanford University School of Medicine, Department of Pharmacology. Dr. Ringold also received a B.S. in biology from the University of California, Santa Cruz. Ringold is qualified to serve on our board of directors due to his significant life science industry experience, including as a chief executive officer, and service on other boards of directors of publicly-traded life sciences companies.
As the Independent Director of Ardelyx Inc, the total compensation of Gordon Ringold at Ardelyx Inc is $144,485. There are 9 executives at Ardelyx Inc getting paid more, with Michael Raab having the highest compensation of $1,728,920.
Gordon Ringold is 69, he's been the Independent Director of Ardelyx Inc since 2014. There are no older and 19 younger executives at Ardelyx Inc.
Gordon's mailing address filed with the SEC is C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT, CA, 94555.
Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Ardelyx Inc executives and other stock owners filed with the SEC include: